PT3305784T - Haptenos de quetiapina para utilização em ensaios imunológicos - Google Patents

Haptenos de quetiapina para utilização em ensaios imunológicos

Info

Publication number
PT3305784T
PT3305784T PT171843402T PT17184340T PT3305784T PT 3305784 T PT3305784 T PT 3305784T PT 171843402 T PT171843402 T PT 171843402T PT 17184340 T PT17184340 T PT 17184340T PT 3305784 T PT3305784 T PT 3305784T
Authority
PT
Portugal
Prior art keywords
quetiapine
haptens
immunoassays
Prior art date
Application number
PT171843402T
Other languages
English (en)
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PT3305784T publication Critical patent/PT3305784T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/16—[b, f]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/77—Ovalbumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
PT171843402T 2012-08-21 2013-08-20 Haptenos de quetiapina para utilização em ensaios imunológicos PT3305784T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261691462P 2012-08-21 2012-08-21

Publications (1)

Publication Number Publication Date
PT3305784T true PT3305784T (pt) 2020-10-23

Family

ID=49081009

Family Applications (2)

Application Number Title Priority Date Filing Date
PT171843402T PT3305784T (pt) 2012-08-21 2013-08-20 Haptenos de quetiapina para utilização em ensaios imunológicos
PT137537775T PT2888257T (pt) 2012-08-21 2013-08-20 Haptenos de quetiapina para utilização em ensaios imunológicos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT137537775T PT2888257T (pt) 2012-08-21 2013-08-20 Haptenos de quetiapina para utilização em ensaios imunológicos

Country Status (10)

Country Link
US (1) US9304126B2 (pt)
EP (2) EP3305784B1 (pt)
JP (1) JP6131415B2 (pt)
CN (2) CN104736536B (pt)
AU (2) AU2013305935B2 (pt)
CA (1) CA2882557C (pt)
ES (2) ES2645433T3 (pt)
PL (2) PL3305784T3 (pt)
PT (2) PT3305784T (pt)
WO (1) WO2014031600A1 (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
CN107253993B (zh) 2012-08-21 2021-10-22 詹森药业有限公司 奥氮平的抗体及其用途
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
ES2788716T3 (es) * 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
PT3305784T (pt) * 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
EP2888285B1 (en) 2012-08-21 2024-04-17 Janssen Pharmaceutica NV Antibodies to aripiprazole haptens and use thereof
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
CA3255043A1 (en) * 2015-02-20 2025-04-02 Idexx Laboratories, Inc. Homogenous immunoassay with compensation for background signal
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
JP6994461B2 (ja) 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ．ベー． クエチアピンに対する抗体及びその使用
MX2020003523A (es) 2017-10-19 2020-07-22 Idexx Lab Inc Deteccion de dimetilarginina simetrica.
US11291861B2 (en) 2019-03-08 2022-04-05 Mevion Medical Systems, Inc. Delivery of radiation by column and generating a treatment plan therefor
CN111808046B (zh) * 2020-06-30 2022-11-11 杭州同舟生物技术有限公司 一种喹硫平人工半抗原、人工抗原及其制备方法和应用
CN116354904B (zh) * 2023-04-26 2023-08-01 北京丹大生物技术有限公司 一种喹硫平衍生物半抗原、抗原、抗喹硫平抗体及其应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
EP0582368B1 (en) 1992-05-29 2001-01-24 Eli Lilly And Company Limited Thienobenzodiazepine derivatives for treatment of CNS disorders
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) * 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
CA2479932A1 (en) 2002-03-28 2003-10-09 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
PT1546134E (pt) 2002-08-05 2007-08-10 Lilly Co Eli ''arilbenzodiazepinas substituídas com piperazina''
PT1664007E (pt) * 2003-09-23 2010-02-15 Fermion Oy Preparação de quetiapina
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) * 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
MX2010003259A (es) * 2007-09-27 2010-04-12 Novartis Ag Ensayo de monitoreo de farmacos.
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
UY32174A (es) 2008-10-14 2010-05-31 Astrazeneca Ab Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
CN104586859B (zh) * 2009-12-31 2017-12-05 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
DK2544536T3 (en) * 2010-03-11 2019-02-04 Kempharm Inc FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
JP5757497B2 (ja) * 2010-10-06 2015-07-29 公立大学法人大阪府立大学 シガトキシン類ｃｔｘ１ｂおよび５４−デオキシ−ｃｔｘ１ｂを認識するモノクローナル抗体およびそれを用いるシガトキシン類検出キット
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
PT3305784T (pt) * 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos

Also Published As

Publication number Publication date
ES2822907T3 (es) 2021-05-05
PL3305784T3 (pl) 2021-03-08
AU2013305935A1 (en) 2015-03-05
JP6131415B2 (ja) 2017-05-24
US20140221616A1 (en) 2014-08-07
PT2888257T (pt) 2017-11-14
CN107266432A (zh) 2017-10-20
EP3305784A1 (en) 2018-04-11
CN107266432B (zh) 2020-05-12
CA2882557C (en) 2020-10-27
HK1211931A1 (en) 2016-06-03
AU2017264980B2 (en) 2019-09-12
CN104736536A (zh) 2015-06-24
ES2645433T3 (es) 2017-12-05
US9304126B2 (en) 2016-04-05
JP2015529198A (ja) 2015-10-05
AU2017264980A1 (en) 2017-12-07
CA2882557A1 (en) 2014-02-27
CN104736536B (zh) 2018-09-25
PL2888257T3 (pl) 2018-02-28
EP3305784B1 (en) 2020-08-12
AU2013305935B2 (en) 2017-08-24
EP2888257B1 (en) 2017-08-02
EP2888257A1 (en) 2015-07-01
WO2014031600A1 (en) 2014-02-27

Similar Documents

Publication Publication Date Title
PL2888257T3 (pl) Hapteny kwetiapiny do zastosowania w testach immunologicznych
PL3663317T3 (pl) Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL2888269T3 (pl) Hapteny olanzapiny
PL2888284T3 (pl) Przeciwciała przeciwko haptenom rysperydonu i ich zastosowanie
ZA201307642B (en) Immunoassay
PT2887952T (pt) Anticorpos para haptenos da olanzapina e suas utilizações
PL2713471T3 (pl) Ładowarka
PL3333195T3 (pl) Przeciwciała względem kwetiapiny i ich zastosowania
EP2888287A4 (en) ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
PL2888234T3 (pl) Hapteny arypiprazolu i ich zastosowanie w testach immunologicznych
PL2888258T3 (pl) Hapteny paliperydonu
EP2690978A4 (en) UNDERWEAR
EP2869799A4 (en) TEXTURED CONDOM
EP2800110A4 (en) CONTACTLESS LOADING DEVICE
EP2793778A4 (en) PLUG
EP2866756A4 (en) BUFFER
GB201120606D0 (en) Inductive device
GB201112395D0 (en) Immunoassay
GB201204932D0 (en) Improvements in arrangements for deploying
SG11201504853VA (en) Immunoassay
GB201217938D0 (en) Immunoassays for meperidine and metabolites
GB201220930D0 (en) Induction charger
GB201109702D0 (en) Magnetometry
GB201110201D0 (en) Immunoassays for meperidine and metabolites
GB201216947D0 (en) Pelvic Hot Waterbottle